AMZNprintsminutestrendsdividendsdrawdownsP/E 28.4macronarrativesvolatilitybuybackssentiment+0.8%marginsMSFTPMI 52.1momentumdividendsflowsPMI 52.1digeststhreadsvolatilityearnings callsvolumesβ 1.24breakoutsnewsflow2s10sliquidityheadlines−1.2%breakoutsnoiseGOOGLbuybacksrevisionstrendsPMI 52.1briefstickersnoiseGDPsentimentchattertranscriptsGOOGLsentimentvolatilitybuybacksMSFTwhispersMETAsessionsyield curves13FfuturesdowngradesPMI 52.1headlinesthe tapeflowsdowngradesfutures+0.8%earnings callstranscriptsclosesgammacatalystsrevisionsvolatilitysentimentchatter+2.41%earnings callssentimentfilingstrends10y 4.21%cyclesbuybackswiresspx 0dtewhisperstickersQ3trendsnewsflowearnings callsWTI 78.2sentimentnoisethreadsrumorsnarrativesFOMCconsensusestimatesmomentumYoY +18%tickersmomentumprintsβ 1.24revisions

momentumheadlines52w hipositioning2s10sfilingstrendsprintstrendsmacrocyclesnoise2s10smacroQ3narrativesheadlinesflowscyclesnarrativesspreadstranscriptsdowngradesupgradeswhisperswhispersminutesthe tapeNDXfuturesminutesyield curves52w hithe tapeFOMCcatalystsbriefsthe tapeNVDAguidancetrends52w hidrawdowns2s10swhispersmomentumdrawdownsbuybacks

PCEliquiditysentimentbreakoutsdowngradesP/E 28.4threadsAAPLSPXvolatilityNDXflowscyclesliquidityestimatesEPS 4.12

INVA · NASDAQ · Biotechnology

Innoviva (INVA)

Funds hospital critical-care and infectious-disease drugs with GSK respiratory royalties.

$20.64

vs last close−0.34 (−1.63%)

In millions of USD, except per-share figures

In millions	Q3 FY23Sep 2023	Q4 FY23Dec 2023	Q1 FY24Mar 2024	Q2 FY24Jun 2024	Q3 FY24Sep 2024	Q4 FY24Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Revenue	67	86	77	103	90	92	89	100	108	118	98	120
Cost of revenue	10	13	11	18	10	7	9	11	26	42	22	29
Gross profit	57	73	67	85	80	85	80	90	82	76	76	91
	33	35	41	30	30	42	121	138	47	37	38	40
Research & development	4	2	4	3	4	4	4	8	14	5	5	5
	0	26	30	28	26	31	27	26	27	32	32	35
General & administrative	0	0	0	0	0	0	0	0	0	0	0	35
Other expenses	29	7	6	0	0	7	89	104	6	0	0	0
Operating income	24	38	26	55	50	43	−41	−49	35	39	38	51
	62	24	19	−94	−43	−18	3	121	63	156	196	−159
Interest income	4	5	4	3	6	6	5	5	5	6	11	8
Interest expense	4	6	6	6	6	5	5	5	4	3	5	5
Other non-operating income	6	−30	−25	88	37	14	−8	−126	−67	−159	−191	−153
Income before tax	86	61	45	−39	7	25	−39	73	98	195	235	−108
Income tax expense	4	0	9	−5	6	4	8	9	8	31	48	−25
Net income from continuing operations	82	62	37	−35	1	20	−47	64	90	164	187	−83
Net income	82	62	37	−35	1	20	−47	64	90	164	187	−83
EPS, basic	$1.26	$0.97	$0.58	−$0.55	$0.02	$0.32	−$0.74	$1.01	$1.30	$2.19	$2.52	−$1.14
EPS, diluted	$0.98	$0.76	$0.46	−$0.55	$0.02	$0.24	−$0.74	$0.77	$1.08	$1.94	$2.22	−$1.14
Weighted average shares, basic	65	64	63	63	63	63	63	63	69	75	74	73
Weighted average shares, diluted	86	85	85	63	63	84	63	84	85	85	85	73
EBITDA	24	74	57	−24	19	36	−27	84	108	208	239	267
Depreciation & amortization	7	7	6	10	7	7	6	7	7	10	10	63
EBIT	18	67	51	−33	13	29	−34	77	102	198	229	204